natgillin/translations-raw huggingface dataset:
Synk tabletten hel sammen med vand. 
Swallow your tablet(s) whole with water.
Alogliptin kan derfor tages med eller uden mad. 
Alogliptin may, therefore, be administered with or without food.
Vurderet ud fra de gennemsnitlige dialysatkoncentrationer blev ca. 7 % af det aktive stof fjernet i løbet af en hæmodialyse af 3 timers varighed). 
Based on mean dialysate concentrations, approximately 7% of the active substance was removed during a 3-hour haemodialysis session.
Interaktionsundersøgelser har vist, at pioglitazon ikke har nogen relevant effekt på hverken farmakokinetik eller farmakodynamik for digoxin, warfarin, phenprocoumon og metformin. 
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin.
En enkelt dosis 50 mg alogliptin blev givet til 4 grupper af patienter med forskellige grader af nedsat nyrefunktion (CrCl beregnet ud fra Cockcroft-Gault-formlen): let nedsat (CrCl = > 50 til ≤ 80 ml/min), moderat nedsat (CrCl = ≥ 30 til ≤ 50 ml/min), svært nedsat (CrCl = < 30 ml/min) eller dialysekrævende terminal nyresygdom. 
A single dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (CrCl using the Cockcroft-Gault formula): mild (CrCl = > 50 to ≤ 80 mL/min), moderate (CrCl = ≥ 30 to ≤ 50 mL/min), severe (CrCl = < 30 mL/min) and end-stage renal disease on haemodialysis.
Samtidig administration af 25 mg alogliptin én gang dagligt og 45 mg pioglitazon én gang dagligt i 12 dage hos raske forsøgspersoner havde ingen klinisk relevant effekt på farmakokinetikken for alogliptin, pioglitazon eller deres aktive metabolitter. 
Co-administration of 25 mg alogliptin once daily and 45 mg pioglitazone once daily for 12 days in healthy subjects had no clinically relevant effects on the pharmacokinetics of alogliptin, pioglitazone or their active metabolites.
Type 2-diabetes kaldes også ikkeinsulinkrævende diabetes mellitus eller gammelmandssukkersyge. 
Type 2 diabetes is also called non-insulin-dependent diabetes mellitus or NIDDM.
Der blev ikke observeret bivirkninger af alogliptin, hvad angår fertilitet, reproduktionsevne eller tidlig embryonal udvikling hos rotter op til en systemisk eksponering, som var langt højere end den humane eksponering ved den anbefalede dosis. 
No adverse effects of alogliptin were observed upon fertility, reproductive performance, or early embryonic development in rats up to a systemic exposure far above the human exposure at the recommended dose.
Patienter med moderat nedsat nyrefunktion (CrCl ≥ 30 til ≤ 50 ml/min) bør have dosis halveret til halvdelen af den anbefalede dosis alogliptin. 
For patients with moderate renal impairment (CrCl ≥ 30 to ≤ 50 mL/min), one-half of the recommended dose of alogliptin should be administered.
Efter administration af orale enkeltdoser på op til 800 mg hos raske personer blev alogliptin hurtigt absorberet, og den højeste plasmakoncentration forekom 1 til 2 timer (median Tmaks) efter administration. 
After administration of single, oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median Tmax) after dosing.
- alogliptin tilhører en gruppe af lægemidler, der kaldes DPP-4-hæmmere (dipeptidyl peptidase-4-hæmmere). 
- alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors).
Tabel 2: Ændring i HbA1c (%) fra baseline til uge 26 i placebokontrollerede studier med alogliptin 25 mg (FAS, LOCF) Studie 
Table 2: Change in HbA1c (%) from baseline with alogliptin 25 mg at Week 26 by placebo-controlled study (FAS, LOCF)
In vitro-studier har vist, at alogliptin inducerer CYP3A4 i mindre grad, men stoffet har ikke vist sig at inducere CYP3A4 i in vivo-studier. 
Studies in vitro have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies in vivo.
Blisterkort af nylon/aluminium/polyvinylklorid (PVC) med aluminiumsfolie, som tabletterne kan trykkes ud igennem. 
Nylon/aluminium/polyvinyl chloride (PVC) blisters with push through aluminium lidding foil.
I dyrestudie med pioglitazon er der ikke fundet nogen effekt på kopulation, befrugtning eller fertilitetsindeks. 
In animal fertility studies conducted with pioglitazone there was no effect on copulation, impregnation or fertility index.
Incresyncs virkning og sikkerhed ved trestofbehandling sammen med sulfonylurinstof er ikke klarlagt, og derfor frarådes kombinationen. 
The efficacy and safety of Incresync as triple therapy with a sulphonylurea has not been established and thus use is not recommended.
Der har været spontane bivirkningsindberetninger i form af akut pancreatitis efter markedsføring. 
There have been spontaneously reported adverse reactions of acute pancreatitis in the post-marketing setting.
I studiet med kardiovaskulære endepunkter var hyppigheden af indberetning af pancreatitis hos patienter, der blev behandlet med alogliptin eller placebo, henholdsvis 3 eller 2 hændelser pr. 1.000 patientår. 
In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively.
Klinisk relevante reduktioner i HbA1c sammenlignet med kontrol blev også observeret uanset lægemiddeldosis for baggrundsbehandling ved baseline. 
Clinically meaningful reductions in HbA1c compared to control were also observed regardless of baseline background medicinal product dose.
- hvis du lider af en hjertesygdom eller af væskeophobning. 
- if you suffer from heart disease or fluid retention.
Forekomsten af frakturer er beregnet til 1,9 frakturer pr. 100 patientår hos de kvinder, der blev behandlet med pioglitazon, og 1,1 frakturer pr. 100 patientår hos de kvinder, der blev behandlet med en komparator. 
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator.
Alogliptin udskilles primært uomdannet i urinen, og omsætning via cytokrom P450 (CYP)enzymsystemet er ubetydelig (se pkt. 
Alogliptin is primarily excreted unchanged in the urine and metabolism by the cytochrome (CYP) P450 enzyme system is negligible (see section 5.2).
- En alvorlig allergisk reaktion: hudlæsioner eller pletter på huden, der kan udvikle sig til et sår omgivet af blege eller røde ringe, blæredannelse og/eller afskalning af huden eventuelt med symptomer som kløe, feber, generel utilpashed, smertende led, synsforstyrrelser, brændende smertefuld eller kløende øjne og sår i munden (Steven-Johnson syndrome og erythema multiforme). 
- A severe allergic reaction: skin lesions or spots on your skin that can progress to a sore surrounded by pale or red rings, blistering and/or peeling of the skin possibly with symptoms such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy eyes and mouth sores (Stevens-Johnson syndrome and Erythema multiforme).
Tabel 3: Ændring i HbA1c (%) fra baseline i aktivt kontrollerede studier af alogliptin 25 mg (PPS, LOCF) 
Table 3: Change in HbA1c (%) from baseline with alogliptin 25 mg by active-controlled study (PPS, LOCF)
Administration af 25 mg alogliptin til patienter med type 2-diabetes mellitus medførte maksimal hæmning af DPP-4 efter 1-2 timer, og hæmningsgraden var på mere end 93 % både efter administration af en enkeltdosis på 25 mg og efter administration af samme dosis én gang dagligt i 14 dage. 
Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing.
Pioglitazons farmakokinetik hos børn og unge under 18 år er ikke klarlagt. 
The pharmacokinetics of pioglitazone in children and adolescents < 18 years old has not been established.
Brug ikke Incresync efter den udløbsdato, der står på pakningen og blisterkortet efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.
Det anbefales derfor, at patienter behandlet med Incresync regelmæssigt får kontrolleret leverenzymer. 
It is recommended, therefore, that patients treated with Incresync undergo periodic monitoring of liver enzymes.
Nervesystemet hovedpine almindelig almindelig hypoæstesi almindelig søvnløshed ikke almindelig 
Nervous system disorders headache common common hypoaesthesia common insomnia uncommon
Kun meget små mængder alogliptin kan fjernes ved hæmodialyse (ca. 7 % af stoffet blev fjernet i løbet af en tretimers-dialysebehandling). 
Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3-hour haemodialysis session).
Lignende ændringer blev observeret hos patienter behandlet med metformin (hæmoglobin: 3-4 % relativ reduktion og hæmatokrit: 3,6-4,1 % relativ reduktion) og i mindre grad hos patienter behandlet med sulfonylurinstof og insulin (hæmoglobin: 1-2 % relativ reduktion og hæmatokrit: 1-3,2 % relativ reduktion) i kontrollerede sammenlignende studier af pioglitazon. 
Similar changes were seen in metformin- (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea- and insulin- (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative-controlled studies with pioglitazone.
Almindelige bivirkninger: - Tegn på lavt blodsukker (hypoglykæmi), som kan opstå, hvis Incresync tages i kombination med insulin eller sulfonylurinstof (f.eks. glipizid, tolbutamid eller glibenclamid). 
Common: - Symptoms of low blood sugar (hypoglycaemia) may occur when Incresync is taken in combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide).
Incresync bør bruges med forsigtighed ved samtidig administration af cytokrom P450 2C8-hæmmere (f.eks. gemfibrozil) eller -induktorer (f.eks. rifampicin). 
Incresync should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin).
Hos patienter med moderat til svært nedsat nyrefunktion eller patienter med hæmodialysekrævende terminal nyresygdom sås en stigning i den systemiske eksponering for alogliptin på henholdsvis ca. 2 og 4 gange. 
In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively.
I aktivt kontrollerede komparator-studier af pioglitazon givet som enkeltstofbehandling var den gennemsnitlige vægtforøgelse 2-3 kg i løbet af et år. 
In active comparator-controlled studies, mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year.
Pioglitazon var uden genotoksisk potentiale i en omfattende række af genotoksicitetsundersøgelser foretaget in vivo og in vitro. 
Pioglitazone was devoid of genotoxic potential in a comprehensive battery of in vivo and in vitro genotoxicity assays.
- forkølelse eller influenzalignende symptomer som ondt i halsen og tilstoppet næse - bihulebetændelse (sinusitis) - hudkløe - hovedpine - mavesmerter - diarré - fordøjelsesbesvær, opstød - almen sygdomsfornemmelse - muskelsmerter - følelsesløshed i en del af kroppen - sløret eller forvrænget syn - vægtforøgelse - hævede hænder eller fødder - udslæt. 
- Cold or flu-like symptoms such as sore throat, stuffy or blocked nose - Inflammation of the sinuses (sinusitis) - Itchy skin - Headache - Stomach ache - Diarrhoea - Indigestion, heartburn - Feeling sick - Muscle pain - Feeling numb in any part of your body - Blurred or distorted vision - Weight gain - Swollen or puffy hands or feet - Rash
Den anbefalede daglige dosis er én tablet a 25 mg/30 mg eller 25 mg/45 mg én gang dagligt, afhængigt af hvilken dosis pioglitazon, der allerede tages. 
The recommended dose is one tablet of 25 mg/30 mg or 25 mg/45 mg once daily, depending on the dose of pioglitazone already being taken.
Der blev ikke observeret nogen klinisk relevant akkumulation efter gentagen administration hos hverken raske forsøgspersoner eller hos patienter med type 2-diabetes mellitus. 
No clinically relevant accumulation after multiple dosing was observed in either healthy subjects or in patients with type 2 diabetes mellitus.
Da det er nødvendigt at justere dosis for alogliptin hos patienter med moderat eller svært nedsat nyrefunktion eller dialysekrævende terminal nyresygdom, anbefales det, at nyrefunktionen vurderes inden igangsættelsen af behandling med Incresync og regelmæssigt derefter (se pkt. 
As there is a need for dose adjustment of alogliptin in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis, appropriate assessment of renal function is recommended prior to initiation of Incresync and periodically thereafter (see section 4.2).
Forekomsten af hypoglykæmi var større, når alogliptin blev anvendt i kombination med både pioglitazon og metformin (sammenlignet med aktiv kontrol). 
The incidence of hypoglycaemia was greater when alogliptin was used as triple therapy with pioglitazone and metformin (compared to active-control).
For at opretholde en systemisk eksponering for alogliptin svarende til den, der er observeret hos patienter med normal nyrefunktion, bør der derfor gives lavere doser alogliptin til patienter med moderat til svært nedsat nyrefunktion eller dialysekrævende terminal nyresygdom (se ovenfor og pkt. 
Therefore, in order to maintain systemic exposures to alogliptin that are similar to those observed in patients with normal renal function, lower doses of alogliptin should be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis (see above and section 4.2).
Metabolisme og ernæring hypoglykæmi almindelig almindelig 
Metabolism and nutrition disorders hypoglycaemia common common
Der er ikke foretaget studier af administration af kombinationen af de aktive stoffer i Incresync til diegivende dyr. 
No studies in lactating animals have been conducted with the combined active substances of Incresync.
- hvis du tager diabetesmedicin af typen sulfonylurinstof (f.eks. glipizid, tolbutamid, glibenclamid) eller insulin. 
- if you are taking an anti-diabetic medicine known as sulphonylurea (e.g. glipizide, tolbutamide, glibenclamide) or insulin.
Der foreligger ingen oplysninger om anvendelse af pioglitazon og alogliptin til dialysepatienter, og derfor bør alogliptin og pioglitazon ikke gives samtidigt til disse patienter (se pkt. 
No information is available on pioglitazone and alogliptin use in dialysed patients and, therefore, co-administered alogliptin plus pioglitazone should not be used in such patients (see sections 4.2 and 5.2).
Overfølsomhedsreaktioner, herunder Stevens-Johnsons syndrom, anafylaktiske reaktioner og angioødem er alvorlige bivirkninger og tilskrives alogliptin-komponenten i Incresync (se pkt. 
Hypersensitivity reactions, including Stevens-Johnson syndrome, anaphylactic reactions, and angioedema are serious and are attributed to the alogliptin component of Incresync (see section 4.4).
I et endepunktsstudie af patienter med betydende makrovaskulær sygdom var forekomsten af alvorlig hjerteinsufficiens ved kombinationsbehandling med insulin 1,6 % højere med pioglitazon end med placebo. 
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo when added to therapy that included insulin.
Mave-tarm-kanalen mavesmerter almindelig almindelig gastroøsofageal reflukssygdom almindelig diarré almindelig dyspepsi almindelig kvalme almindelig akut pancreatitis ikke kendt 
Gastrointestinal disorders abdominal pain common common gastroesophageal reflux disease common diarrhoea common dyspepsia common nausea common acute pancreatitis not known
Tag altid lægemidlet nøjagtigt efter lægens, eller apotekspersonalets anvisning. 
Always take this medicine exactly as your doctor or pharmacist has told you.
Placebokontrollerede studier med kombinationsbehandling som tillæg Alogliptin 25 mg én gang dagligt med pioglitazon ± metformin eller et sulfonylurinstof (n = 195) FAS = fuldt analysesæt LOCF (last observation carried forward) = sidste observation ekstrapoleret † Mindste kvadraters gennemsnit justeret mht. tidligere antihyperglykæmisk behandlingsstatus og baselineværdier * p < 0,001 sammenlignet med placebo eller placebo + kombinationsbehandling 
Add-on combination therapy placebo-controlled studies Alogliptin 25 mg once daily with pioglitazone ± metformin or a sulphonylurea (n=195) FAS = full analysis set LOCF = last observation carried forward † Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values * p<0.001 compared to placebo or placebo+combination treatment
Incresync-tabletter indeholder lactose. 
Incresync tablets contain lactose.
I kliniske studier af en varighed på op til to år reducerede pioglitazon totalplasmatriglycerider og frie fedtsyrer og forøgede HDL-kolesterolniveauet sammenlignet med placebo, metformin eller gliclazid. 
In clinical studies of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels compared to placebo, metformin or gliclazide.
I alt 3.504 patienter med type 2-diabetes mellitus, herunder 1.908 patienter, som blev behandlet med alogliptin og pioglitazon, deltog i 4 dobbeltblindede, placebo- eller aktivt kontrollerede kliniske fase III-studier, som blev gennemført for at evaluere virkningen af samtidig administration af alogliptin og pioglitazon på den glykæmiske kontrol samt disse stoffers sikkerhed. 
A total of 3,504 patients with type 2 diabetes mellitus, including 1,908 patients treated with alogliptin and pioglitazone, participated in 4 phase 3 double-blind, placebo- or active-controlled clinical studies conducted to evaluate the effects of co-administered alogliptin and pioglitazone on glycaemic control and their safety.
De foreliggende data er baseret på i alt 3.504 patienter med type 2-diabetes mellitus, herunder 1.908 patienter, som blev behandlet med alogliptin og pioglitazon, og som deltog i 4 dobbeltblindede, placebo- eller aktivt kontrollerede kliniske fase III-studier. 
The information provided is based on a total of 3,504 patients with type 2 diabetes mellitus, including 1,908 patients treated with alogliptin and pioglitazone, who participated in 4 phase 3 double-blind, placebo- or active-controlled clinical studies.
Incresync kan derfor tages med eller uden mad. 
Incresync may, therefore, be administered with or without food.
DPP-4 er det primære enzym, der indgår i den hurtige nedbrydning af inkretinhormonerne GLP-1 (glukagonlignende peptid-1) og GIP (glucoseafhængigt insulinotropisk polypeptid). 
DPP-4 is the principal enzyme involved in the rapid degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and GIP (glucosedependent insulinotropic polypeptide), which are released by the intestine and levels are increased in response to a meal.
Der blev observeret frakturer hos 2,6 % af de kvinder, der blev behandlet med pioglitazon, sammenlignet med 1,7 % af de kvinder, der blev behandlet med en komparator. 
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator.
I kliniske studier havde alogliptin ingen klinisk relevant indvirkning på farmakokinetikken for koffein, (R)-warfarin, pioglitazon, glyburid, tolbutamid, (S)-warfarin, dextromethorphan, atorvastatin, midazolam (et oralt kontraceptivum indeholdende norethindron og ethinyløstradiol), digoxin, fexofenadin, metformin eller cimetidin, hvilket giver in vivo-evidens for stoffets lave tilbøjelighed til at forårsage interaktion med substrater af CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glykoprotein og OCT2. 
In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.
Der sås øget forekomst af hyperplasi (hos hanner og hunner) og tumorer (hos hanner) i urinblærens epitel hos rotter behandlet med pioglitazon i op til 2 år. 
An increased incidence of hyperplasia (males and females) and tumours (males) of the urinary bladder epithelium was apparent in rats treated with pioglitazone for up to 2 years.
Glycerol mono-oleat 
Carnauba wax Glycerol mono-oleate Glycerol mono-oleate
Patienter, som skifter fra separate tabletbehandlinger med henholdsvis alogliptin og pioglitazon til Incresync, skal fortsætte med den daglige dosis alogliptin og pioglitazon, der allerede indtages. 
For patients switching from separate tablets of alogliptin and pioglitazone, both alogliptin and pioglitazone should be dosed at the daily dose already being taken.
Mikrokrystallinsk cellulose Hydroxypropylcellulose Croscarmellosenatrium Magnesiumstearat Lactosemonohydrat 
Microcrystalline cellulose Hydroxypropylcellulose Croscarmellose sodium Magnesium stearate Lactose monohydrate
Incresync skal tages én gang dagligt alene eller i forbindelse med et måltid. 
Incresync should be taken once daily with or without food.
Hyperplasi af urinblæren sås ikke hos hunde eller aber behandlet med pioglitazon i op til 12 måneder. 
There was no tumourigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.
Der skal udvises forsigtighed, når alogliptin bruges i kombination med metformin og et thiazolidindion, da der er observeret en øget risiko for hypoglykæmi ved denne kombinationsbehandling med 3 aktive substanser (se pkt. 
Caution should be exercised when alogliptin is used in combination with metformin and a thiazolidinedione as an increased risk of hypoglycaemia has been observed with this triple therapy (see section 4.4).
Alogliptin var ikke teratogent hos rotter og kaniner, der blev udsat for systemisk eksponering med NOAEL, der var langt højere end den humane eksponering ved den anbefalede dosis. 
Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose.
Næsten alle patienterne (95 %) var i behandling med kardiovaskulære lægemidler (betablokkere, ACE-hæmmere, angiotensin II-antagonister, kalciumantagonister, nitrater, diuretika, acetylsalisylsyre, statiner og fibrater). 
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).
En metaanalyse af kontrollerede kliniske studier af pioglitazon (19 tilfælde ud af 12.506 patienter, 0,15 %) viste en øget forekomst af blærecancer sammenlignet med kontrolgruppen (7 tilfælde ud af 10.212 patienter, 0,07 %) - HR = 2,64 (95 % konfidensinterval 1,11 - 6,31, p = 0,029). 
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical studies with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029).
En samlet analyse af data fra 12 studier viste, at den samlede forekomst af hypoglykæmi var den samme for patienter på 65 år og derover behandlet med 25 mg alogliptin (3,8 %) som for patienter under 65 år (3,6 %). 
In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients ≥ 65 years old treated with 25 mg alogliptin (3.8%) to that in patients < 65 years old (3.6%).